Related Experiment Videos
Acetylator polymorphism in Alzheimer's disease
J M Ladero1, M S Barquero, F Coria
1Service of Gastroenterology, Hospital Universitario de San Carlos, University Complutense (Department of Medicine), Madrid, Spain.
The European Journal of Medicine
|May 1, 1993
Summary
This study found no link between genetic acetylator polymorphism and Alzheimer's disease risk. The prevalence of slow acetylators was similar in patients and controls, indicating no association.
Area of Science:
- Neuroscience
- Genetics
- Pharmacogenomics
Background:
- Alzheimer's disease (AD) is a complex neurodegenerative disorder with multifactorial etiology.
- Genetic factors play a significant role in AD susceptibility.
- Acetylator polymorphism, a heritable trait affecting drug metabolism, has been investigated for potential links to various diseases.
Purpose of the Study:
- To investigate the potential association between genetic acetylator polymorphism and the risk of developing Alzheimer's disease.
- To determine if slow acetylator status influences AD onset or severity.
Main Methods:
- A case-control study was conducted with 54 Alzheimer's disease patients and 93 age-matched controls.
- Acetylator polymorphism was assessed using sulphamethazine.
- Cognitive function was evaluated using the Minimental State Examination and Blessed, Tomlinson & Roth scale.
Main Results:
- The distribution of slow acetylators was not significantly different between Alzheimer's disease patients (57.4%) and controls (58%).
- No correlation was observed between acetylator polymorphism and age at disease onset.
- Acetylator status did not correlate with cognitive scores on the Minimental State Examination or Blessed, Tomlinson & Roth scale.
Conclusions:
- The findings do not support a relationship between genetic acetylator polymorphism and the risk of developing Alzheimer-type dementia.
- Acetylator status does not appear to be a significant genetic risk factor for Alzheimer's disease.